TCF7L2 and neoplasm: Patients with nHM tumours with SMAD4 deletion had shorter RFS (HR = 2.13, 95% CI = 1.04–4.34), and those with TCF7L2 translocation had shorter OS (HR = 4.82, 95% CI = 2.10–11.03) and RFS (HR = 7.50, 95% CI = 2.72–20.69; Supplementary Table 23).